WuXi AppTec completes $135 million acquisition of Oxgene

The addition further strengthens WuXi's cell and gene therapy service offerings for global customers and will be Wuxi ATU's first facility in Europe

This acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cell and gene therapies for patients in need worldwide.

Oxgene will become a fully-owned subsidiary of WuXi Advanced Therapies (WuXi ATU), WuXi AppTec’s cell and gene therapy contract testing, development and manufacturing organization (CTDMO) business unit.

Oxgene, which will retain its name, will be WuXi ATU’s first facility in Europe and will further enhance its capabilities.

Since its founding in 2011, Oxgene has offered discovery and biomanufacturing solutions to the cell and gene therapy industries through novel technologies and contract research solutions.

It also provides manufacturing systems that deliver scalability. Oxgene’s novel TESSA technology for adeno-associated viral (AAV) manufacturing and XLenti stable solutions for lentiviral manufacturing simplify cell and gene therapy manufacturing and significantly reduce costs.

Dr Ryan Cawood, Founder and Chief Executive Officer of Oxgene said the companies' combined business will strengthen and broaden its service offerings for customers, improving by "orders of magnitude" the scale and cost of bringing cell and gene therapies to market.